logo
logo

Takeda To Acquire Nimbus Therapeutics’ Highly Selective, Allosteric Tyk2 Inhibitor To Address Multiple Immune-Mediated Diseases

Dec 13, 2022•over 2 years ago

Acquiring Company

Takeda Pharmaceuticals

Acquired Company

Nimbus Therapeutics

TokyoTherapeuticsPharmaceuticalBiotechnologyHealth Care

Description

Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced that it has signed a definitive agreement under which Takeda (TSE:4502/NYSE:TAK) will acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858 is an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis.

Company Information

Company

Takeda Pharmaceuticals

Location

Tokyo, Tokyo, Japan

About

Takeda Pharmaceuticals is Japan's largest drugmaker. It has transformed into one of the world's leading pharmaceutical companies under CEO Christophe Weber. The company operates in approximately 80 countries and focuses on high-impact therapeutic areas. Takeda is committed to scaling innovation capabilities and shaping the future of global healthcare.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Related People

Julie hidden

Julie hidden

Milano hidden